MarketCapExport financials
ICU Medical (ICUI)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
ICU Medical Financial Ratios 2025-2006 | ICUI
Brief overview of ICU Medical's financial ratios
Current figures are compared with the company's own five-year history for 2021–2025.
The current valuation set is EV/EBITDA 13.8x (median 13.8x), P/S 1.64x (median 1.64x), P/B 0.91x (median 0.91x). Ratios sit near their own comparison base, with an average deviation of 0% from five-year medians.
The latest available business-quality ratios are ROE 0%, ROA 0%, ROCE 2%. Profitability sends a weak positive signal and leaves the business sensitive to cost or demand pressure.
The cash conversion cycle lengthened from 131.9 days to 146 days, or 14.1 days. More cash is tied up in operations.
Overall assessment
ICU Medical's multiples form a balanced picture without a clear discount or premium. Future appeal depends on earnings and return trends.
Annual Financial Ratios ICU Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5011.8 | -31.0 | -86.4 | -57.1 | 48.7 | 49.9 | 37.9 | 170.2 | 66.4 | 34.7 | 33.9 | 48.5 | 23.6 | 20.8 | 14.2 | 14.1 | 21.8 | 14.8 | 25.5 | - | |
P/S |
1.6 | 1.5 | 1.1 | 1.9 | 3.8 | 3.4 | 3.0 | 3.5 | 3.5 | 5.8 | 4.5 | 4.1 | 3.0 | 2.7 | 2.1 | 1.5 | 2.4 | 1.8 | 3.1 | - |
EPS |
0.0 | -4.8 | -1.2 | -3.1 | 4.9 | 4.2 | 4.9 | 1.4 | 3.5 | 3.9 | 2.8 | 1.7 | 2.8 | 2.9 | 3.2 | 2.2 | 1.7 | 1.7 | 1.6 | - |
EV (Enterprise Value) |
3.36 B | 3.34 B | 2.31 B | 4.03 B | 4.47 B | 3.94 B | 3.87 B | 4.88 B | 4.56 B | 1.79 B | 1.24 B | 1.03 B | 761 M | 750 M | 575 M | 343 M | 493 M | 305 M | 580 M | -13.2 M |
EBITDA per Share |
9.89 | 10.8 | 10.4 | 8.05 | 10 | 8.79 | 11.2 | 12.9 | 7.01 | 7.3 | 6.31 | 4.16 | 4.86 | 5.64 | 4.83 | 4.78 | 3.47 | 3.22 | 2.55 | - |
EV/EBITDA |
13.8 | 12.7 | 9.2 | 21.0 | 23.5 | 16.9 | 15.4 | 17.3 | 31.0 | 14.8 | 11.9 | 15.8 | 10.2 | 8.9 | 8.0 | 5.3 | 9.7 | 6.7 | 15.9 | - |
PEG |
1314.12 | -28.27 | 39.97 | -6.48 | 4.07 | 4.07 | 0.15 | -2.85 | -6.47 | 0.93 | 0.52 | -1.29 | -4.55 | -2.04 | 0.34 | - | - | - | - | - |
P/B |
0.9 | 0.9 | 0.6 | 0.9 | 2.7 | 2.5 | 2.8 | 3.9 | 3.8 | 3.3 | 2.6 | 2.5 | 2.0 | 2.2 | 2.0 | 1.4 | 1.8 | 1.3 | - | - |
P/CF |
20.4 | 17.9 | 15.4 | -68.3 | 18.8 | 19.5 | -928.0 | 82.4 | 61.0 | 33.5 | 37.3 | 29.7 | 20.6 | 18.7 | 13.0 | 12.8 | 10.6 | 11.9 | 14.2 | - |
ROE % |
0.03 | -5.99 | -1.40 | -3.55 | 6.38 | 5.78 | 7.34 | 2.28 | 5.73 | 9.56 | 7.76 | 5.18 | 8.70 | 10.56 | 13.93 | 11.01 | 9.48 | 9.60 | 10.79 | - |
ROA % |
0.02 | -2.80 | -0.68 | -1.65 | 5.48 | 4.93 | 5.97 | 1.82 | 4.59 | 8.95 | 7.18 | 4.87 | 8.09 | 9.63 | 12.37 | 9.66 | 8.08 | 8.57 | - | - |
ROCE % |
2.02 | 2.19 | 1.07 | -2.05 | 7.63 | 6.53 | 10.13 | 14.15 | 5.51 | 14.91 | 14.01 | 8.61 | 10.99 | 15.34 | 14.61 | 17.54 | 13.45 | 12.40 | 11.52 | - |
Current Ratio |
- | - | - | - | - | - | 3.6 | 3.7 | 4.1 | 14.0 | 11.8 | 15.2 | 14.7 | 11.2 | 8.9 | - | - | - | - | - |
DSO |
29.7 | 26.4 | 31.0 | 26.2 | 31.9 | 46.9 | 59.6 | 52.5 | 62.0 | 54.0 | 61.8 | 46.1 | 52.7 | 56.6 | 52.6 | 63.7 | 68.7 | 34.3 | - | - |
DIO |
155.5 | 151.7 | 168.8 | 113.8 | 133.9 | 147.1 | 155.1 | 136.8 | 121.6 | 101.0 | 99.0 | 85.4 | 79.1 | 82.7 | 92.3 | - | - | - | - | - |
DPO |
39.2 | 34.9 | 44.0 | 34.3 | 33.9 | 45.2 | 59.1 | 53.0 | 33.0 | 30.0 | 31.0 | 26.3 | 26.0 | 25.7 | 30.3 | - | - | - | - | - |
Operating Cycle |
185.2 | 178.0 | 199.8 | 140.0 | 165.8 | 194.0 | 214.7 | 189.4 | 183.6 | 155.1 | 160.8 | 131.5 | 131.8 | 139.3 | 144.9 | 63.7 | 68.7 | 34.2 | - | - |
Cash Conversion Cycle |
146.0 | 143.1 | 155.8 | 105.7 | 131.9 | 148.8 | 155.6 | 136.4 | 150.6 | 125.0 | 129.8 | 105.2 | 105.8 | 113.5 | 114.7 | 63.7 | 68.7 | 34.2 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios ICU Medical
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q4 | 2009-Q3 | 2009-Q2 | 2009-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
1.07 | 0.76 | 1.22 | - | -0.14 | 1.43 | -0.63 | - | -1.35 | -0.88 | -1.63 | - | 0.3 | -0.41 | -0.41 | - | -0.55 | -0.31 | -1.61 | - | 1.47 | 1.34 | 1.12 | 1.24 | 1.19 | 0.91 | 1.72 | 1 | 1.29 | 1.11 | 1.51 | -0.36 | 0.01 | 1.53 | 0.24 | 2.47 | 0.01 | -1.87 | 3.03 | 0.58 | 1.16 | 1.03 | 1.13 | 0.34 | 1.02 | 0.86 | 0.62 | 0.48 | 0.42 | 0.39 | 0.44 | 0.89 | 0.75 | 0.5 | 0.6 | 0.86 | 0.85 | 0.65 | 0.54 | 1.29 | 0.66 | 0.69 | 0.59 | 0.71 | 0.67 | 0.57 | 0.31 | - | 0.43 | 0.39 | 0.48 |
EBITDA per Share |
3.41 | 5.55 | 2.57 | - | 1.27 | 1.12 | 2.54 | - | 1.21 | 1.23 | 1.85 | - | 1.98 | 1.13 | 1.74 | - | 0.94 | 1.04 | 0.46 | - | 4.95 | 3.72 | 2.3 | - | 4.28 | 1.69 | 4.23 | - | 4.35 | 3.11 | 2.41 | - | 2.8 | 3.32 | 1.15 | - | 2.19 | -0.3 | -0.29 | - | 2.27 | 2.01 | 1.79 | - | 2.39 | 1.86 | 0.99 | - | 1.5 | 1.2 | 0.97 | - | 2.03 | 1.41 | 1.15 | - | 2.22 | 1.63 | 1.16 | - | 1.94 | 1.66 | 1.22 | - | 2.03 | 1.51 | 0.79 | - | 1.28 | 1.08 | 0.97 |
ROE % |
3.38 | 3.82 | 2.16 | 0.73 | -0.88 | -1.77 | -5.35 | -4.57 | -4.22 | -3.08 | -2.50 | -0.59 | -1.25 | -1.95 | -3.23 | -2.76 | -0.81 | 1.67 | 3.59 | 5.34 | 7.08 | 6.79 | 6.30 | 6.00 | 5.76 | 6.03 | 6.34 | 7.34 | 5.26 | 3.34 | 4.14 | 2.28 | 7.01 | 7.00 | 1.45 | 5.73 | 3.02 | 5.86 | 11.47 | 9.56 | 9.06 | 9.01 | 8.84 | 7.76 | 8.27 | 6.73 | 5.54 | 5.18 | 6.60 | 7.71 | 8.14 | 8.70 | 8.99 | 9.73 | 10.49 | 10.56 | 12.97 | 12.74 | 13.36 | 13.93 | 11.93 | 12.46 | 12.65 | 11.87 | 10.59 | 9.31 | 8.86 | 7.13 | 2.28 | 2.14 | 2.70 |
ROA % |
1.83 | 2.01 | 1.16 | 0.41 | -0.36 | -0.77 | -2.56 | -2.19 | -2.02 | -1.48 | -1.20 | -0.28 | -0.57 | -0.90 | -1.48 | -1.26 | 0.43 | 2.30 | 3.81 | 4.61 | 6.09 | 5.82 | 5.26 | 4.99 | 4.73 | 4.88 | 5.21 | 5.97 | 4.29 | 2.73 | 3.34 | 1.82 | 5.60 | 5.60 | 1.16 | 4.59 | 2.61 | 5.27 | 10.11 | 8.95 | 8.47 | 8.40 | 8.21 | 7.18 | 7.67 | 6.26 | 5.18 | 4.87 | 6.17 | 7.19 | 7.58 | 8.09 | 8.30 | 8.94 | 9.60 | 9.63 | 11.69 | 11.41 | 11.91 | 12.37 | 10.56 | 10.98 | 11.04 | 10.29 | 9.20 | 8.13 | 7.84 | 6.36 | 2.04 | 1.92 | 2.40 |
ROCE % |
5.49 | 3.61 | 2.44 | 1.79 | 2.20 | 1.93 | 0.91 | 0.26 | 1.35 | 1.08 | 1.15 | 1.67 | 1.64 | 0.55 | -1.51 | -1.96 | 0.45 | 2.69 | 4.44 | 6.37 | 8.07 | 7.05 | 7.87 | 6.12 | 8.51 | 8.72 | 9.54 | 6.50 | 6.68 | 6.80 | 5.28 | 3.08 | 2.77 | -0.41 | -4.34 | -4.72 | -1.32 | 2.43 | 9.06 | 10.48 | 14.75 | 14.85 | 13.30 | 9.67 | 11.32 | 8.76 | 7.20 | 5.31 | 8.63 | 9.33 | 10.20 | 8.26 | 12.75 | 12.89 | 13.45 | 10.86 | 15.01 | 14.88 | 15.23 | 12.31 | 17.89 | 18.57 | 16.79 | 12.98 | 15.74 | 13.40 | 12.68 | 10.09 | 2.76 | 3.23 | 4.10 |
DSO |
31.7 | 31.8 | 32.8 | - | 31.5 | 29.1 | 26.7 | - | 25.2 | 22.7 | 24.7 | - | 26.7 | 25.1 | 29.0 | - | 32.7 | 34.1 | 17.1 | - | 32.1 | 34.2 | 35.1 | 35.3 | 46.1 | 48.4 | 23.6 | 58.5 | 60.0 | 59.1 | 52.2 | 47.3 | 49.2 | 44.6 | 35.4 | 27.8 | 30.0 | 31.0 | 31.1 | 53.6 | 52.8 | 53.0 | 57.9 | 58.4 | 61.4 | 63.0 | 54.3 | 44.6 | 46.0 | 45.3 | 52.6 | 53.1 | 49.9 | 52.6 | 58.0 | 54.2 | 55.1 | 58.0 | 56.0 | 52.0 | 52.0 | 51.1 | 60.3 | 64.8 | 63.0 | 64.7 | 68.5 | - | 50.7 | 49.4 | - |
DIO |
170.2 | 174.8 | 172.0 | - | 168.2 | 161.6 | 135.9 | - | 163.2 | 161.4 | 167.8 | - | 189.6 | 194.7 | 174.9 | - | 134.0 | 129.8 | 100.8 | - | 129.5 | 138.1 | 136.6 | - | 142.2 | 147.6 | 73.6 | - | 163.1 | 147.8 | 151.3 | - | 147.4 | 136.1 | 122.7 | - | 113.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
40.9 | 46.6 | 46.2 | - | 46.2 | 46.8 | 38.0 | - | 38.5 | 36.1 | 36.2 | - | 39.1 | 45.2 | 48.7 | - | 45.1 | 46.7 | 34.4 | - | 28.9 | 32.9 | 32.2 | - | 38.6 | 40.0 | 22.6 | - | 62.1 | 56.3 | 58.1 | - | 57.1 | 52.7 | 40.6 | - | 30.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
201.9 | - | - | - | 199.7 | 190.7 | 162.6 | - | 188.5 | 184.1 | 192.4 | - | 216.3 | - | 203.9 | - | 166.7 | 163.9 | 126.7 | - | 161.7 | 172.3 | 171.7 | 35.3 | 188.3 | 196.0 | 97.2 | 58.5 | 223.1 | 206.9 | 203.5 | 47.3 | 196.6 | 180.7 | 158.1 | 27.8 | 143.7 | 31.0 | 31.1 | 53.6 | 52.8 | 53.0 | 57.9 | 58.4 | 61.4 | 63.0 | 54.3 | 44.6 | 46.0 | 45.3 | 52.6 | 53.1 | 49.9 | 52.6 | 58.0 | 54.2 | 55.1 | 58.0 | 56.0 | 52.0 | 52.0 | 51.1 | - | 64.8 | - | - | - | - | - | - | - |
Cash Conversion Cycle |
161.0 | - | - | - | 153.5 | 143.9 | 124.6 | - | 150.0 | 147.9 | 156.3 | - | 177.2 | - | 155.2 | - | 121.6 | 117.2 | 92.3 | - | 132.8 | 139.4 | 139.5 | 35.3 | 149.7 | 156.0 | 74.6 | 58.5 | 161.0 | 150.6 | 145.4 | 47.3 | 139.5 | 128.0 | 117.5 | 27.8 | 112.8 | 31.0 | 31.1 | 53.6 | 52.8 | 53.0 | 57.9 | 58.4 | 61.4 | 63.0 | 54.3 | 44.6 | 46.0 | 45.3 | 52.6 | 53.1 | 49.9 | 52.6 | 58.0 | 54.2 | 55.1 | 58.0 | 56.0 | 52.0 | 52.0 | 51.1 | - | 64.8 | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company ICU Medical, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
BioLife Solutions
BLFS
|
$ 38.61 | 3.51 % | $ 1.84 B |  USA |
 |
Alcon
ALC
|
$ 74.11 | -1.37 % | $ 36.6 B |  Schweiz |
 |
Baxter International
BAX
|
$ 26.43 | 0.06 % | $ 13.6 B | USA |
 |
The Cooper Companies
COO
|
$ 63.6 | -0.52 % | $ 12.7 B | USA |
 |
electroCore
ECOR
|
$ 7.68 | 6.96 % | $ 65.1 M | USA |
 |
ResMed
RMD
|
$ 234.15 | -0.67 % | $ 34.1 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.55 | -1.5 % | $ 16.5 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 24.25 | -1.22 % | $ 1.2 B | USA |
 |
STERIS plc
STE
|
$ 257.0 | 0.02 % | $ 25.2 B | USA |
 |
Teleflex Incorporated
TFX
|
$ 155.37 | 0.27 % | $ 6.93 B | USA |
 |
Utah Medical Products
UTMD
|
$ 72.86 | -0.01 % | $ 236 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 412.49 | -0.08 % | $ 29.8 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 15.24 | 3.81 % | $ 315 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 9.77 | 2.36 % | $ 1.95 B | USA |
 |
iRhythm Technologies
IRTC
|
$ 86.01 | -3.07 % | $ 2.75 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 449.99 | -2.3 % | $ 161 B | USA |
 |
Repro Med Systems
KRMD
|
$ 3.17 | -1.86 % | $ 146 M | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 213.55 | -1.21 % | $ 61.4 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
AtriCure
ATRC
|
$ 56.21 | -2.74 % | $ 2.68 B | USA |
 |
AngioDynamics
ANGO
|
$ 12.07 | -0.45 % | $ 501 M | USA |
 |
Glaukos Corporation
GKOS
|
$ 236.28 | -1.03 % | $ 13.5 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 9.39 | 3.3 % | $ 417 M | USA |
 |
OraSure Technologies
OSUR
|
$ 3.41 | -3.54 % | $ 251 M | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Microbot Medical
MBOT
|
$ 1.06 | -4.09 % | $ 48.5 M |  Israel |
 |
Haemonetics Corporation
HAE
|
$ 122.34 | 3.49 % | $ 5.77 B | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.3 | -0.36 % | $ 24.6 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 87.87 | -0.62 % | $ 5.2 B | USA |
 |
Nephros
NEPH
|
$ 3.13 | 4.33 % | $ 33.2 M | USA |
 |
Pro-Dex
PDEX
|
$ 70.6 | 0.43 % | $ 228 B | USA |
 |
Envista Holdings Corporation
NVST
|
$ 25.87 | -0.19 % | $ 4.35 B | USA |
 |
LeMaitre Vascular
LMAT
|
$ 78.94 | -2.74 % | $ 1.79 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 55.1 | -5.28 % | $ 3.71 B | USA |
 |
Repligen Corporation
RGEN
|
$ 174.04 | -2.74 % | $ 9.79 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
- | - | $ 9.59 B | USA |
 |
Stereotaxis
STXS
|
$ 1.05 | -7.89 % | $ 95.5 M | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |